CTOs on the Move

Alamar Biosciences

www.alamarbio.com

 
Alamar Biosciences is a biotechnology company that has developed a next generation proteomic platform with ultra high sensitivity and multiplexing capability for plasma protein detection and liquid biopsies.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Tides Medical

Tides Medical is a privately funded medical technology firm located in Lafayette, LA, is a leader in the growing market for amniotic membrane technology. Our focus is on providing patients with safe, effective therapies, physicians with reliable produc...

LC Sciences

LC Sciences is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Solarea Bio

Solarea Bio is a preclinical-stage biotechnology company in Cambridge, MA developing new microbiome-based solutions to some of the world`s largest health problems.

Isis Pharmaceuticals Inc

Isis Pharmaceuticals Inc is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PDL BioPharma

PDL manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has invested approximately $780 million to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its shareholders. The Company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue.